Group 1 - The core viewpoint of the article highlights the significant stock performance of CSPC Pharmaceutical Group, which saw a 5.17% increase, reaching HKD 10.38 per share with a trading volume of HKD 1.605 billion [1] - CSPC Pharmaceutical Group is a Hong Kong-listed pharmaceutical company primarily engaged in the production of finished drugs and active pharmaceutical ingredients, with a strategic focus on innovative drugs [1] - The company has a strong product portfolio in therapeutic areas such as neurological diseases, oncology, anti-infection, and cardiovascular diseases, supported by an international R&D team [1] Group 2 - As of the first quarter of 2025, CSPC Pharmaceutical Group reported total revenue of HKD 7.015 billion and a net profit of HKD 1.478 billion [2]
石药集团(01093)上涨5.17%，报10.38元/股